Meanwhile, other siRNA drug candidates, JNJ-75220795 (ARO-PNPLA3)363 and ALN-PNP, designed for reducing PNPLA3 expression, are also undergoing phase 1 trials for NASH treatment (NCT04844450, NCT05039710, and NCT05648214). This evidence concerns the gene PNPLA3 and metabolic dysfunction-associated steatohepatitis.